Fusion Pharmaceuticals Alpha and Beta Analysis
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Fusion Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Fusion Pharmaceuticals over a specified time horizon. Remember, high Fusion Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Fusion Pharmaceuticals' market risk premium analysis include:
Beta 0.29 | Alpha 0.0202 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Fusion |
Fusion Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Fusion Pharmaceuticals market risk premium is the additional return an investor will receive from holding Fusion Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Fusion Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Fusion Pharmaceuticals' performance over market.| α | 0.02 | β | 0.29 |
Fusion Pharmaceuticals Fundamentals Vs Peers
Comparing Fusion Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fusion Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Fusion Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fusion Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fusion Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Fusion Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Fusion Pharmaceuticals to competition |
| Fundamentals | Fusion Pharmaceuticals | Peer Average |
| Return On Equity | -0.47 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Operating Margin | (54.04) % | (5.51) % |
| Current Valuation | 1.69 B | 16.62 B |
| Shares Outstanding | 85.06 M | 571.82 M |
| Shares Owned By Insiders | 0.46 % | 10.09 % |
| Shares Owned By Institutions | 86.80 % | 39.21 % |
Fusion Pharmaceuticals Opportunities
Fusion Pharmaceuticals Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Fusion Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Fusion or other delisted stocks. Alpha measures the amount that position in Fusion Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Fusion Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Fusion Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fusion Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Fusion Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Fusion Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Fusion Pharmaceuticals' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Fusion Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |